Can Biotech Kill the Flu Once and For All?
Biotech is essential for advancing science. Biotechnology is a broad term that involves the use of living organisms to develop new products. Over the...
Capturing the Deep Ocean on Film with Ed McNichol of Ocean Exploration Trust
Considering that our oceans cover more than 70 percent of our planet’s surface and contain more than 97 percent of the Earth’s water, it’s...
What to Check Out at the AAAS Annual Meeting in Washington, D.C.
The American Association for the Advancement of Science (AAAS) is hosting its annual meeting to offer more than 120 scientific sessions to grow awareness...
Scientists Crack Framework to Control Leg Movement of MicroRobots
Animals that live and move primarily on land navigate over their natural terrains using a set of complex leg trajectories.
Individual animal leg trajectories are...
The Tools Leading The Science Community to New Discoveries
Many of our technological advances are used first by the scientific community. Nuclear magnetic resonance machines to analyze molecular structures were turned in the...
Biotech IPOs For This Week
(RTTNews) - In the healthcare sector, only 1 company made its stock market debut in January.
Now, let's take a look at the U.S. biotech...
Too Little Sleep May Boost Your Risk of Cardiovascular Disease
Participants in the study who slept less than six hours a night were 27% more likely to develop plaque buildup in their arteries. The...
Look into the Future with This ‘Crystal Ball’ Spherical Sun Power Generator
A German Architect has designed an innovative form of a solar power generator. Unlike being flat or thin like other PV panels, this one is...
Almost 25% of Prescribed Antibiotics Are Unnecessary, Says Study
A study published in the medical journal The BMJ showed that 23 percent of prescriptions from 2016 in the United States were unnecessary.
The most common conditions...
The Daily Biotech Pulse: Roche Scraps Alzheimer’s Disease Trials, Amgen Issues Weak Guidance
Roche Holdings AG Basel ADR Common Stock RHHBY 0.03% said it plans to discontinue its late-stage studies dubbed CREAD 1 and 2 that evaluate its crenezumab...
Related Posts
